病理検査サービスの日本市場（2026年～2034年）

• 英文タイトル：Japan Pathology Lab Services Market Size, Share, Trends and Forecast by Type, Testing Service, End Use, and Region, 2026-2034

• レポートコード：SR112026A37101 • 出版社/出版日：IMARC / 2026年1月 • レポート形態：英語、PDF、100ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥619,845 (USD3,999)	▷ お問い合わせ
Corporate User	￥929,845 (USD5,999)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

日本の病理検査サービス市場規模は2025年に349億2550万米ドルに達した。今後、IMARCグループは2034年までに市場規模が773億9330万米ドルに達し、2026年から2034年にかけて年平均成長率（CAGR）9.24％で成長すると予測している。デジタル病理学とAIの急速な普及が市場を牽引しており、デジタル医療変革と精密医療を推進する政府施策がこれを後押ししている。高齢者の増加と慢性疾患の蔓延により、ゲノム検査と個別化診断の需要が高まっており、検査機関は次世代シーケンシング（NGS）とバイオマーカー分析の能力強化を迫られている。病理検査機関、AIスタートアップ、製薬企業間の戦略的提携がイノベーションを加速させ、日本の病理検査サービス市場シェアをさらに拡大している。 市場ではデジタル病理学と人工知能（AI）統合への大きな転換が進行中である。全スライド画像（WSI）技術とクラウドベースデータストレージの進歩により、検査室は従来の顕微鏡検査からデジタルプラットフォームへ移行し、より迅速かつ正確な診断を実現している。AI搭載ツールは病理医の異常検出支援、人的ミスの削減、ワークフロー効率化のために採用が拡大している。日本政府のデジタル医療変革推進と精密医療需要の高まりがこの傾向を加速させている。2024年度予算ではデジタルヘルス分野が大幅に増額され617億円（約4億米ドル）に達し、高齢化に伴う病理サービス需要増に対応するため、AI診断と電子カルテ（EMR）の導入に重点が置かれている。政府推計では2040年までに96万人の医療従事者不足が予測されており、検査・診断分野におけるデジタル技術の迅速な導入が急務である。日米協力では現在、EMR標準化、病理分野のAI開発、検査インフラのデジタル刷新に向けた越境データ交換が焦点となっている。さらに、病理検査室とAIスタートアップの連携により、特にがん検出分野における自動診断技術の革新が進んでいる。ただし、導入コストの高さやデータセキュリティへの懸念といった課題は残る。こうした障壁があるにもかかわらず、特に地方部における拡張性と遠隔対応を備えた診断ソリューションの需要拡大が、今後10年間で日本のデジタル病理学導入をさらに促進すると予想される。 ゲノム検査と個別化医療への需要加速が、日本の病理検査サービス市場成長を大きく支えている。高齢化社会の進展と慢性疾患の増加に直面する中、遺伝子プロファイリングに基づく個別化治療戦略の重要性がますます高まっている。日本の炎症性腸疾患（IBD）発生率は2022年の368.3件/10万人から、2032年には645.8件/10万人に増加すると予測される。年間5.78%の増加率で推移し、18歳未満の患者層で最も高い上昇率が報告される見込みである。潰瘍性大腸炎も引き続き主要な亜型と予測され、2032年の推定有病率は10万人あたり545.9人と、クローン病の101.9人を上回る。慢性疾患の増加傾向は、日本の炎症性腸疾患（IBD）医療システムにおいて、病理検査施設の拡充と小児診断能力の向上が喫緊の課題であることを示している。病理検査室は、精密がん治療や希少疾患診断を支援するため、次世代シーケンシング（NGS）やバイオマーカー解析の能力を拡大中だ。「すべての国民のための医療政策」などの政府施策がゲノム医療を推進しており、市場成長をさらに加速させている。民間検査機関も製薬企業と連携し、標的療法向けコンパニオン診断薬の開発を進めている。高コストや規制上の複雑さはあるものの、個別化医療への移行は日本の病理分野における長期的な成長を持続させると予想され、検査機関は精密医療の推進において重要な役割を担う。 日本の病理検査サービス市場セグメンテーション： IMARC Groupは、各市場セグメントの主要トレンド分析に加え、2026年から2034年までの国別・地域別予測を提供しています。本レポートでは、市場をタイプ別、検査サービス別、エンドユース別に分類しています。 タイプ別インサイト： 病院内検査室 独立検査室 診断チェーン 本レポートでは、タイプ別（病院内独立検査室、診断チェーン）の詳細な市場分析を提供。 検査サービス別分析： 一般生理学的・臨床検査 画像・放射線検査 特殊検査 COVID-19検査 検査サービス別の詳細な市場分析も本レポートで提供。これには、一般生理学的・臨床検査、画像・放射線検査、特殊検査、COVID-19検査が含まれます。 最終用途別インサイト： 医師紹介 ウォークイン 法人 本レポートでは、最終用途に基づく市場の詳細な分析と分類を提供しています。これには、医師紹介、ウォークイン、法人が含まれます。

The Japan pathology lab services market size reached USD 34,925.5 Million in 2025. Looking forward, IMARC Group expects the market to reach USD 77,393.3 Million by 2034, exhibiting a growth rate (CAGR) of 9.24% during 2026-2034. The market is driven by the rapid adoption of digital pathology and AI, supported by government initiatives promoting digital healthcare transformation and precision medicine. The increasing number of elderly individuals and the prevalence of chronic illnesses are driving the need for genomic testing and personalized diagnostics, prompting laboratories to enhance their capabilities in next-generation sequencing (NGS) and biomarker analysis. Strategic collaborations between pathology providers, AI startups, and pharmaceutical firms are accelerating innovations, further augmenting the Japan pathology lab services market share.

The market is witnessing a significant shift toward digital pathology and artificial intelligence (AI) integration. With advancements in whole-slide imaging (WSI) and cloud-based data storage, labs are transitioning from traditional microscopy to digital platforms for faster and more accurate diagnostics. AI-powered tools are being increasingly adopted to assist pathologists in detecting anomalies, reducing human error, and improving workflow efficiency. The Japanese government’s push for digital healthcare transformation, along with rising demand for precision medicine, is accelerating this trend. Japan’s fiscal year 2024 budget for digital health has risen substantially to JPY 61.7 billion (approximately USD 400 Million), with an emphasis on AI diagnostics and the inclusion of electronic medical records (EMRs) to meet the increased need for pathology services resulting from an aging population. Government estimates predict a shortage of 960,000 healthcare professionals by 2040, which underscores the need for swift implementation of digital technologies in the laboratory and diagnostic sectors. United States-Japan collaborations are now focused on EMR standardization, AI development in pathology, and cross-border data exchange to digitally revamp laboratory infrastructure. Additionally, collaborations between pathology labs and AI startups are fostering innovation in automated diagnosis, particularly in cancer detection. However, challenges such as high implementation costs and data security concerns remain. Despite these barriers, the growing need for scalable and remote diagnostic solutions, especially in rural areas, is expected to drive further adoption of digital pathology in Japan over the next decade.

The accelerating demand for genomic testing and personalized medicine is significantly supporting the Japan pathology lab services market growth. As the nation confronts an increasing elderly population and a higher incidence of chronic illnesses, there is an intensifying emphasis on customized treatment strategies informed by genetic profiling. The incidences of inflammatory bowel disease (IBD) in Japan are projected to be 645.8 per 100,000 by 2032, up from 368.3 in 2022. It will increase at an annual rate of 5.78%, with the highest rise reported in patients under 18 years of age. Ulcerative colitis is also projected to continue being the major subtype in Japan with an estimated prevalence of 545.9 per 100,000 in 2032, higher than Crohn’s disease at 101.9. The rising epidemic of chronic illness shows the pressing necessity of upgrading pathology laboratory facilities and upgrading pediatric diagnostic capacity in Japan’s IBD care system. Pathology labs are expanding their capabilities to include next-generation sequencing (NGS) and biomarker analysis to support precision oncology and rare disease diagnosis. Government initiatives, such as the “Healthcare Policy for All Citizens,” are promoting genomic medicine, further propelling market growth. Private labs are also partnering with pharmaceutical companies to develop companion diagnostics for targeted therapies. Despite the high costs and regulatory complexities, the shift toward personalized healthcare is expected to sustain long-term growth in Japan’s pathology sector, with labs playing a crucial role in advancing precision medicine.

Japan Pathology Lab Services Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the country and regional levels for 2026-2034. Our report has categorized the market based on type, testing service, and end use.

Type Insights:

Hospital-based
Standalone Labs
Diagnostic Chains
The report has provided a detailed breakup and analysis of the market based on the type. This includes hospital-based, standalone labs, and diagnostic chains.

Testing Service Insights:

General Physiological and Clinical Tests
Imaging and Radiology Tests
Esoteric Tests
COVID-19 Tests
A detailed breakup and analysis of the market based on the testing service have also been provided in the report. This includes general physiological and clinical tests, imaging and radiology tests, esoteric tests, and COVID-19 tests.

End Use Insights:

Physician Referral
Walk-in
Corporate

The report has provided a detailed breakup and analysis of the market based on the end use. This includes physician referral, walk-in, and corporate.

レポート目次

---

1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Japan Pathology Lab Services Market – Introduction
4.1 Overview
4.2 Market Dynamics
4.3 Industry Trends
4.4 Competitive Intelligence
5 Japan Pathology Lab Services Market Landscape
5.1 Historical and Current Market Trends (2020-2025)
5.2 Market Forecast (2026-2034)
6 Japan Pathology Lab Services Market – Breakup by Type
6.1 Hospital-based
6.1.1 Overview
6.1.2 Historical and Current Market Trends (2020-2025)
6.1.3 Market Forecast (2026-2034)
6.2 Standalone Labs
6.2.1 Overview
6.2.2 Historical and Current Market Trends (2020-2025)
6.2.3 Market Forecast (2026-2034)
6.3 Diagnostic Chains
6.3.1 Overview
6.3.2 Historical and Current Market Trends (2020-2025)
6.3.3 Market Forecast (2026-2034)
7 Japan Pathology Lab Services Market – Breakup by Testing Service
7.1 General Physiological and Clinical Tests
7.1.1 Overview
7.1.2 Historical and Current Market Trends (2020-2025)
7.1.3 Market Forecast (2026-2034)
7.2 Imaging and Radiology Tests
7.2.1 Overview
7.2.2 Historical and Current Market Trends (2020-2025)
7.2.3 Market Forecast (2026-2034)
7.3 Esoteric Tests
7.3.1 Overview
7.3.2 Historical and Current Market Trends (2020-2025)
7.3.3 Market Forecast (2026-2034)
7.4 COVID-19 Tests
7.4.1 Overview
7.4.2 Historical and Current Market Trends (2020-2025)
7.4.3 Market Forecast (2026-2034)
8 Japan Pathology Lab Services Market – Breakup by End Use
8.1 Physician Referral
8.1.1 Overview
8.1.2 Historical and Current Market Trends (2020-2025)
8.1.3 Market Forecast (2026-2034)
8.2 Walk-in
8.2.1 Overview
8.2.2 Historical and Current Market Trends (2020-2025)
8.2.3 Market Forecast (2026-2034)
8.3 Corporate
8.3.1 Overview
8.3.2 Historical and Current Market Trends (2020-2025)
8.3.3 Market Forecast (2026-2034)
9 Japan Pathology Lab Services Market – Breakup by Region
9.1 Kanto Region
9.1.1 Overview
9.1.2 Historical and Current Market Trends (2020-2025)
9.1.3 Market Breakup by Type
9.1.4 Market Breakup by Testing Service
9.1.5 Market Breakup by End Use
9.1.6 Key Players
9.1.7 Market Forecast (2026-2034)
9.2 Kansai/Kinki Region
9.2.1 Overview
9.2.2 Historical and Current Market Trends (2020-2025)
9.2.3 Market Breakup by Type
9.2.4 Market Breakup by Testing Service
9.2.5 Market Breakup by End Use
9.2.6 Key Players
9.2.7 Market Forecast (2026-2034)
9.3 Central/ Chubu Region
9.3.1 Overview
9.3.2 Historical and Current Market Trends (2020-2025)
9.3.3 Market Breakup by Type
9.3.4 Market Breakup by Testing Service
9.3.5 Market Breakup by End Use
9.3.6 Key Players
9.3.7 Market Forecast (2026-2034)
9.4 Kyushu-Okinawa Region
9.4.1 Overview
9.4.2 Historical and Current Market Trends (2020-2025)
9.4.3 Market Breakup by Type
9.4.4 Market Breakup by Testing Service
9.4.5 Market Breakup by End Use
9.4.6 Key Players
9.4.7 Market Forecast (2026-2034)
9.5 Tohoku Region
9.5.1 Overview
9.5.2 Historical and Current Market Trends (2020-2025)
9.5.3 Market Breakup by Type
9.5.4 Market Breakup by Testing Service
9.5.5 Market Breakup by End Use
9.5.6 Key Players
9.5.7 Market Forecast (2026-2034)
9.6 Chugoku Region
9.6.1 Overview
9.6.2 Historical and Current Market Trends (2020-2025)
9.6.3 Market Breakup by Type
9.6.4 Market Breakup by Testing Service
9.6.5 Market Breakup by End Use
9.6.6 Key Players
9.6.7 Market Forecast (2026-2034)
9.7 Hokkaido Region
9.7.1 Overview
9.7.2 Historical and Current Market Trends (2020-2025)
9.7.3 Market Breakup by Type
9.7.4 Market Breakup by Testing Service
9.7.5 Market Breakup by End Use
9.7.6 Key Players
9.7.7 Market Forecast (2026-2034)
9.8 Shikoku Region
9.8.1 Overview
9.8.2 Historical and Current Market Trends (2020-2025)
9.8.3 Market Breakup by Type
9.8.4 Market Breakup by Testing Service
9.8.5 Market Breakup by End Use
9.8.6 Key Players
9.8.7 Market Forecast (2026-2034)
10 Japan Pathology Lab Services Market – Competitive Landscape
10.1 Overview
10.2 Market Structure
10.3 Market Player Positioning
10.4 Top Winning Strategies
10.5 Competitive Dashboard
10.6 Company Evaluation Quadrant
11 Profiles of Key Players
11.1 Company A
11.1.1 Business Overview
11.1.2 Services Offered
11.1.3 Business Strategies
11.1.4 SWOT Analysis
11.1.5 Major News and Events
11.2 Company B
11.2.1 Business Overview
11.2.2 Services Offered
11.2.3 Business Strategies
11.2.4 SWOT Analysis
11.2.5 Major News and Events
11.3 Company C
11.3.1 Business Overview
11.3.2 Services Offered
11.3.3 Business Strategies
11.3.4 SWOT Analysis
11.3.5 Major News and Events
11.4 Company D
11.4.1 Business Overview
11.4.2 Services Offered
11.4.3 Business Strategies
11.4.4 SWOT Analysis
11.4.5 Major News and Events
11.5 Company E
11.5.1 Business Overview
11.5.2 Services Offered
11.5.3 Business Strategies
11.5.4 SWOT Analysis
11.5.5 Major News and Events

Company names have not been provided here as this is a sample TOC. Complete list to be provided in the final report.

12 Japan Pathology Lab Services Market – Industry Analysis
12.1 Drivers, Restraints, and Opportunities
12.1.1 Overview
12.1.2 Drivers
12.1.3 Restraints
12.1.4 Opportunities
12.2 Porters Five Forces Analysis
12.2.1 Overview
12.2.2 Bargaining Power of Buyers
12.2.3 Bargaining Power of Suppliers
12.2.4 Degree of Competition
12.2.5 Threat of New Entrants
12.2.6 Threat of Substitutes
12.3 Value Chain Analysis
13 Appendix

---